⭐️What to look 👀 for in your urine for cancer? Honored to film this public announcement for cancer awareness @BladderCancerUS @WorldBladderCan @IBCG_BladderCA @AmericanCancer #PatientCare #Healthcare #CancerAwareness #KnowledgeCanDiminishFear

The future of cancer care won't be built by immunotherapy alone—or by AI alone. It will be built at the intersection of both. I'm honored to have been invited by Technology Networks as a Featured Oral Speaker for The Landscape of Cancer Research: Advances in Immuno-Oncology 2026, where I'll be discussing Artificial Intelligence in Lymphoma Immunotherapy. From clinical trial matching and precision treatment selection to uncovering patterns we might otherwise miss, AI is rapidly becoming a powerful tool to augment oncology care. While there is still much work ahead, the potential impact on patients is enormous. Grateful to Technology Networks for the invitation and excited to learn from an incredible lineup of speakers advancing the future of cancer research. I would also like to thank Dr. Arturo LoAIza-Bonilla and Dr. Chandler Park for their mentorship, encouragement, and friendship. Much of what I have learned about innovation, leadership, and translating emerging technologies into meaningful impact for patients has been shaped by mentors who invest deeply in the next generation. I am profoundly grateful for their guidance. 📅 June 17–18, 2026 🌍 Free Global Virtual Event Join us: technologynetworks.com/tn/on… #CancerResearch #ImmunoOncology #ArtificialIntelligence #Lymphoma #PrecisionMedicine #Hematology #Oncology #CancerInnovation

Honored to attend the 2026 @ASCOPost Advisory Board Meeting at #ASCO26 in Chicago as an Associate Editor. We discussed how to share oncology updates clearly and responsibly. Photo: Matt Herp. #ConexiantAtASCO @ASCO @VivekSubbiah @jamecancerdoc @RManochakian #JimArmitage @caraglynn01 @CharuAggarwalMD @OncoAlert @OpenMedicineHQ @NagiSaghir

This is very important unless the PDL1 is very high like 80% we use chemo/IO as standard of care but there was still debate #lungcancer #lscm

It was a wonderful honor to join our annual @NCCN #CLL #SLL #Richters #HCL panel repping @RoswellPark with amazing colleagues from around 🇺🇸 in Philadelphia on the eve of America’s 250th birthday. Doing our best in a (fortunately) rapidly changing and improving landscape to guide physicians and other #cancer providers in helping patients fight blood cancers more safely, effectively, and tolerably. #lymsm #leuksm #bloodcancer

It was truly an honor to join Matthew Zachary on Out of Patients. Matthew is a brain cancer survivor, patient advocate, and one of the most influential voices in cancer survivorship. Sitting down with someone who has spent decades fighting for patients made this conversation especially meaningful. We talked about a journey that began long before medicine—from surviving the aftermath of the Chernobyl disaster as a child, to caring for my mother during her cancer journey, to ultimately choosing a career in oncology. Along the way, we discussed mentorship, resilience, patient advocacy, the challenges facing American healthcare, and the responsibility we have to leave medicine better than we found it. One thought that has stayed with me throughout my career is this: "Every physician has a story, but not every physician remembers what it feels like to be the patient." That perspective has shaped how I approach medicine, leadership, education, and service. At its core, this conversation isn't really about Chernobyl or even medicine. It's about purpose—how adversity can shape us, how mentors can change the course of our lives, and how our greatest challenges can become opportunities to serve others. I'm grateful to the physicians who cared for me, the mentors who guided me, the patients who trust me, and to Matthew for creating a space where these conversations can happen. 🎙️ The Chernobyl Kid in a White Coat open.spotify.com/episode/7bh… I hope you'll give it a listen, and I'd love to hear what resonates most with you. #Oncology #Medicine #PatientAdvocacy #CancerCare #Mentorship #Leadership #Healthcare #Survivorship #Chernobyl #OutOfPatients

BLESSED BEYOND MEASURE for the opportunity of a LIFETIME to speak at the 2026 @ASCO lung orals session as the discussant on FOUR impactful abstracts focused on novel therapeutic strategies for small cell lung cancer! These trials represent HOPE through progress, dedicated research, discovery, curiosity, and serve as new/future options for our Small Cell SMASHERS & their loved ones. Deeply grateful for this opportunity to highlight the key aspects of each study and how we can use this knowledge to help change/improve the way we treat, care for, and support our patients all over the world impacted by small cell lung cancer. Thank you to every patient, SMASHER, and loved ones who dedicated their lives to be parts of these studies. Because of your courage, altruism, and selflessness, we are one more step closer to limiting loss from small cell lung cancer. #ASCO2026 #researchcurescancer #lcsm #trials #research @SclcSMASHERS @ConquerCancerFd @IUCancerCenter @LUNGevity @TheShieldsLab @LauraAlderMD @FordePatrick @LaurenByersMD @g_mountzios

Congratulations to the #ASCO26 leaders and top influencers! 🇺🇸 Your presentations, coverage, and impact have been outstanding. Massive thanks for pushing oncology forward and making this meeting unforgettable! Huge shoutout to @OncoAlert for connecting us all 🙌 @DrChoueiri @GlopesMd @montypal @tompowles1 @PGrivasMDPhD @brian_rini @TiansterZhang @nataliagandur @CParkMD @realbowtiedoc @DrYukselUrun @weoncologists @urotoday @OncBrothers @neerajaiims @crisbergerot @StephenVLiu @zklaassen_md #ASCO26 #OncoAlert #Oncology #CancerResearch #ASCO2026

Congratulations to my mentee @JeffreyYZhong for being selected for this BCAN honor based on his work on real world outcomes with enfortumab vedotin dose reductions! @UHhospitals @caseccc @PBarataMD @koshkin85 @PGrivasMDPhD Also kudos to my MSTP colleague @curtperrymdphd as well

Attending the ASCO Global leaders alumni meeting was a great experience. Dr. Eric Small (ASCO president and senior colleague) really verbalized the value of mentoring through ASCO and it's global impact.

What a creative way of managing hope and treatment. MBC pt on SG plans to paint healing energies into her PET scan images every SG she gets! Her vision is to see clear scans over time! @MCWCancerCenter @Froedtert #BreastCancer #clinicaltrials

🎗️ ASCO 2026 Recap 📝 As Chandler Park @CParkMD said, "Science moves fast. Oncology news moves faster." ASCO 2026 showcased major advances in ADCs, cell therapy, precision oncology, MRD detection, and next-generation cancer therapeutics. Here are the highlights we picked from X during #ASCO26 👇 @semodough $COGT: Detailed PEAK Phase 3 Bezuclastinib Sunitinib Data in GIST » x.com/semodough/status/20607… @jfais20 $REPL: RP1 Data Strengthens the Case Against the "Fluke" Narrative » x.com/jfais20/status/2060752… @DrRishabhOnco 15 ASCO 2026 Trials That Could Move the Needle » x.com/DrRishabhOnco/status/2… @JacobPlieth $GILD: TUB-040 ORR Improves to 61% as Responses Continue to Deepen » x.com/JacobPlieth/status/206… @doepke_michel $PSNL: New Data Highlights Early Recurrence Detection and Ultrasensitive MRD Performance » x.com/doepke_michel/status/2… @BioStocks $ONC: BRUKINSA Sets New Long-Term CLL Benchmark with 78-Month PFS Data » x.com/BioStocks/status/20603… @ohadhammer Topo1 ADCs Dominate ASCO 2026, with China Behind 23 of 31 Phase 1 Programs » x.com/ohadhammer/status/2056… @GIMedOnc $PFE: Lorlatinib Delivers 55% 7-Year PFS in Landmark CROWN Update » x.com/GIMedOnc/status/206056… @Quantumup1 $IDYA: Analysts Highlight Undervalued MUM Opportunity Following ASCO Update » x.com/Quantumup1/status/2061… @SuyogCancer PD-L1 × VEGF Bispecific Shows Encouraging First-Line NSCLC Activity in ROSSETTA Lung-02 » x.com/SuyogCancer/status/206… @DrSamuelBHume $GRAL: Galleri Misses Primary Goal, but Trial Signals Potential for Earlier Cancer Detection » x.com/DrSamuelBHume/status/2… @bioinvestor24 $IMTX: PRAME TCR Therapy Delivers 63% ORR in Gynecologic Cancers » x.com/bioinvestor24/status/2… @adamfeuerstein $RVMD: Incredible Moment: Daraxonrasib Data Draws Rare Mid-Presentation Standing Ovation » x.com/adamfeuerstein/status/… @TalhaBadarMD Triplet Therapy Delivers 79% 3-Year OS in Newly Diagnosed IDH1-Mutant AML » x.com/TalhaBadarMD/status/20… @EricTopol $MRNA $MRK: Personalized mRNA Vaccine Shows 49% Reduction in Recurrence and Death at 5 Years » x.com/EricTopol/status/20614… @BiotechObserver PD-1/VEGF Bispecifics Face Their Biggest Test as Global Phase 3 Trials Advance » x.com/BiotechObserver/status… @HHorinouchi AEGEAN: Durvalumab Shifts Tumors Toward Activated Immune States, Driving Strongest EFS Benefit in C3 Patients » x.com/HHorinouchi/status/206… @dr_yakupergun $AZN $DSNKY: Dato-DXd Extends Benefit Beyond Progression in 1L mTNBC » x.com/dr_yakupergun/status/2…

We know Black men are at higher risk for #prostatecancer & that a variant T allele increases their risk 3.4 x. The news: if someone has 2 of these T alleles, risk appears 11.4 x. Listen as McManus & Shevach discuss. #ASCO26 @DukeGUCancer @DukeCancer @DukeHealth

Science travels farther when opportunity is shared. Thank you ASCO and Conquer Cancer for empowering the next generation through education, mentorship, and opportunity. #ASCO26 @ASCO @ASCOPres @ConquerCancerFd @OncoAlert @jrgralow @CliffordHudis

Dear Colleagues at #ASCO26 🇺🇸 A Great way to start the Final day of the meeting, our sincere thanks to @ASCO faculty and staff for a magnificent meeting!! 3⃣5⃣3⃣Million Impressions 1⃣9⃣.3⃣K Posts 1⃣.4⃣K Participants Thanking our Colleagues worldwide for their support! WE ARE ALL @OncoAlert 🚨 As Always. For Colleagues.....By Colleagues @DrChoueiri @urotoday @GlopesMd @montypal @OncBrothers @tompowles1 @neerajaiims @PGrivasMDPhD @brian_rini @nataliagandur @crisbergerot @NEJM @OncoReporte @CParkMD @realbowtiedoc @MoffittNews @StephenVLiu @zklaassen_md @RenoHemonc @DrYukselUrun @AmandaBinDC

Burada asıl haber tek bir rakam değil. Mesele sadece sağkalımın iki katına çıkmış olması da değil. Asıl haber, “imkansız” denilen kapının aralanmış olması. Çünkü RAS, sadece pankreasta değil, birçok kanserin ortak hikayesinde var. Bu yolun sonu değil, başlangıcı. Ama uzun süredir az seçeneği olan insanlar için yeni bir kapı açıldı. @ASCO @OncoAlert @OpenMedicineHQ @DanaFarber_Hale #asco26

I told them we’re going to #ASCO26 and when we arrived they thought I said #COSTCO 20 years from now I hope we look back and at this memory and say, “remember when we couldn’t cure #pancreaticcancer ?” #KRASG12 #daraxonrasib @RevMedicines

The most trusted voice in cancer care @ASCOPost It is an honor for me to be appointed as the Senior Deputy Editor of @ASCOPost The voice of @ASCO ! Grateful to the very talented editorial board, leadership of Dr. Jim Armitage EIC, @caraglynn01 and Angela Cochran!

Truck test ✅✅✅

With all the excitement around daraxonrasib, I needed to refresh my RAS inhibitor knowledge, so here we go:

Great insights from The Oncology Forum GU panel at #ASCO26! Practical discussion translating key GU oncology updates into real-world practice. Thank you @PGrivasMDPhD @CParkMD @katy_beckermann for an excellent session!